Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures
Haemophilia · 2025-09 · 31 (5) · 1003-1007
DOI: 10.1111/hae.70052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 29.04.2025. Verfasst von Neta Sternbach und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center Petah-Tikva, Petah-Tikva, Israel. Hauptthemen laut MEDLINE: Tranexamic Acid, Factor VIIa, Factor XI Deficiency, Urologic Surgical Procedures. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients with severe Factor XI deficiency face unique challenges during urological procedures due to an elevated risk of bleeding, balanced against the use of tranexamic acid (TXA), which may form blood clots. Given the limitations associated with plasma‐based treatment, there have been reports of successful and safe off‐label use of recombinant activated Factor VII (rFVIIa) in combination with TXA in general surgery.
Aim
Report our experience with this approach in urological surgeries involving tissues with heightened fibrinolytic activity.
Methods
A retrospective case series analysed seven patients with severe FXI deficiency who underwent seven urological procedures. Five patients were classified as bleeders, and two developed antibodies to FXI following prior exposure to plasma. The use of off‐label rFVIIa was approved by our institutional authorities. Patients received TXA 1 g four times daily for 7–10 days, and a single dose of 10–15 mcg/kg of rFVIIa at the end of surgery (based on previous thrombin generation studies). Patients were connected to a continuous irrigation system postoperatively and monitored for urinary bleeding.
Results
All procedures were performed without significant bleeding complications, except for one patient who remained on aspirin therapy and experienced manageable bleeding. None of the patients required discontinuation of TXA due to blood clots, nor did they require blood transfusions or additional doses of rFVIIa. No thrombotic complications were observed.
Conclusion
Combination of low‐dose rFVIIa with TXA is a feasible and attractive option for patients undergoing urologic procedures. Further implications of this protocol should be implemented in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center Petah-Tikva, Petah-Tikva, Israel.
- Department of Urology, Rabin Medical Center, Petah Tikva, Israel.
- Department of Urology, Meir Medical Center, Kfar Saba, Israel.
- School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
ORCID-Profile: Neta Sternbach
Zitieren
APA
Sternbach, N., Ehrlich, Y., Stenevsky, A., Saidian, D., Elhalim, D. A., Baniel, J., Raanani, P., & Spectre, G. (2025). Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures. Haemophilia, 31(5), 1003-1007. https://doi.org/10.1111/hae.70052
Vancouver
Sternbach N, Ehrlich Y, Stenevsky A, Saidian D, Elhalim DA, Baniel J, et al. Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures. Haemophilia. 2025;31(5):1003-1007. doi:10.1111/hae.70052
BibTeX
@article{Sternbach2025,
author = {Sternbach, Neta and Ehrlich, Yaron and Stenevsky, Anfisa and Saidian, Daniel and Elhalim, Darawsha Abd and Baniel, Jack and Raanani, Pia and Spectre, Galia},
title = {Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures},
journal = {Haemophilia},
year = {2025},
volume = {31},
number = {5},
pages = {1003--1007},
doi = {10.1111/hae.70052}
}
EUVIMED